CMN548-
M.5 PRACTICE QUESTIONS AND ANSW
ff ff f ff
ERS WITH SOLUTIONS 2025
ff ff ff
35.1. Theff time,f f course,f f andf f intensityf f off f af f drug'sf f effectf f aref f referredf f tof f as:
A. pharmacokinetics
B. pharmacodynamics
C. pharmacogenetics
D. placebof f effect
E. idiosyncraticff reactionff -f f correctf f answer-B.f f pharmacodynamics
35.2. Neuroleptic-
inducedffmovementffdisordersffincludeffwhichffofffthefffollowingff
movementffdisorders?
A. Acutef f dystonia
B. Neurolepticff malignantff syndrome
C. Akathisia
D. Tardiveffdyskinesia
E. Allf f off f thef f abovef f -f f correctf f answer-E.f f Allf f off f thef f above
35.3. Clonidinef f (Catapres)f f isf f knownff tof f bef f effectivef f in
A. Tourette'sffdisorder
B. attention-deficit/hyperactivityffdisorder
C. opiatef f withdrawal
D. posttraumaticff stressf f disorder
E. allf f off f thef f abovef f -f f correctf f answer-E.f f allf f off f thef f above
35.4. Therapeuticffindicationsffofffβ-
adrenergicffreceptorffantagonistsffsuchffasffpropranololff(Inderal),ffatenololff(Tenormin),
metoprololff(Lopressor),ffnadololff(Corgard),ffandffpindololff(Viske
n)ffareffeffectiveffinffthefftreatmentffof
A. lithiumf f tremor
, B. substanceff usef f disorders
C. violence
D. performanceff anxieties
E. allf f off f thef f abovef f -f f correctf f answer-E.f f allf f off f thef f above
35.5. Infftheffelderlyffpopulation,ffanticholinergicffmedications
ff canffproduce
A. improvementf f off f positivef f symptomsf f off f psychosis
B. improvedffstorageffofffnewffinformationffintofflong-
termffmemory
C. worseningff ideationalff apraxia
D. impairmentf f inf f cognitiveff functioning
E. worseningf f offf orientationf f subscalesf f -f f correctf f answer-D.ff impairmentf f inff cognitivef f functioning
35.6. Newerffanticonvulsantsffsuchffasffgabapentinff(Neurontin),
ff levetiracetamff(Keppra),ffpregabalinff(Lyrica),fftiagabine
(Gabitril),fftopiramateff(Topamax),ffandffzonisamideff(Zonegran)ffhaveffdemonstratedffwhichffofffthefffollow
ingffcharacteristics?
A. Enhancingf f neuronalf f inhibition
B. Analgesicff effects
C. Increasedf f riskf f off f suicidality
D. Decreasingff glutamicf f function
E. Allf f off f thef f abovef f -f f correctf f answer-E.f f Allf f off f thef f above
35.7. H2ffreceptorffantagonistffnizatidineff(Axid)ffisffefficaciousffas
f f affsecondaryffpreventionffstrategyffforffassociatedffweight
gainffinffwhichffoneffofffthefffollowingffantipsychoticffdrug
s?
A. Olanzapineff (Zyprexa)
B. Quetiapineff (Seroquel)
M.5 PRACTICE QUESTIONS AND ANSW
ff ff f ff
ERS WITH SOLUTIONS 2025
ff ff ff
35.1. Theff time,f f course,f f andf f intensityf f off f af f drug'sf f effectf f aref f referredf f tof f as:
A. pharmacokinetics
B. pharmacodynamics
C. pharmacogenetics
D. placebof f effect
E. idiosyncraticff reactionff -f f correctf f answer-B.f f pharmacodynamics
35.2. Neuroleptic-
inducedffmovementffdisordersffincludeffwhichffofffthefffollowingff
movementffdisorders?
A. Acutef f dystonia
B. Neurolepticff malignantff syndrome
C. Akathisia
D. Tardiveffdyskinesia
E. Allf f off f thef f abovef f -f f correctf f answer-E.f f Allf f off f thef f above
35.3. Clonidinef f (Catapres)f f isf f knownff tof f bef f effectivef f in
A. Tourette'sffdisorder
B. attention-deficit/hyperactivityffdisorder
C. opiatef f withdrawal
D. posttraumaticff stressf f disorder
E. allf f off f thef f abovef f -f f correctf f answer-E.f f allf f off f thef f above
35.4. Therapeuticffindicationsffofffβ-
adrenergicffreceptorffantagonistsffsuchffasffpropranololff(Inderal),ffatenololff(Tenormin),
metoprololff(Lopressor),ffnadololff(Corgard),ffandffpindololff(Viske
n)ffareffeffectiveffinffthefftreatmentffof
A. lithiumf f tremor
, B. substanceff usef f disorders
C. violence
D. performanceff anxieties
E. allf f off f thef f abovef f -f f correctf f answer-E.f f allf f off f thef f above
35.5. Infftheffelderlyffpopulation,ffanticholinergicffmedications
ff canffproduce
A. improvementf f off f positivef f symptomsf f off f psychosis
B. improvedffstorageffofffnewffinformationffintofflong-
termffmemory
C. worseningff ideationalff apraxia
D. impairmentf f inf f cognitiveff functioning
E. worseningf f offf orientationf f subscalesf f -f f correctf f answer-D.ff impairmentf f inff cognitivef f functioning
35.6. Newerffanticonvulsantsffsuchffasffgabapentinff(Neurontin),
ff levetiracetamff(Keppra),ffpregabalinff(Lyrica),fftiagabine
(Gabitril),fftopiramateff(Topamax),ffandffzonisamideff(Zonegran)ffhaveffdemonstratedffwhichffofffthefffollow
ingffcharacteristics?
A. Enhancingf f neuronalf f inhibition
B. Analgesicff effects
C. Increasedf f riskf f off f suicidality
D. Decreasingff glutamicf f function
E. Allf f off f thef f abovef f -f f correctf f answer-E.f f Allf f off f thef f above
35.7. H2ffreceptorffantagonistffnizatidineff(Axid)ffisffefficaciousffas
f f affsecondaryffpreventionffstrategyffforffassociatedffweight
gainffinffwhichffoneffofffthefffollowingffantipsychoticffdrug
s?
A. Olanzapineff (Zyprexa)
B. Quetiapineff (Seroquel)
